Characteristic | Placebo, n = 223 | Treatment Group Milnacipran 100 mg/day, n = 224 | Milnacipran 200 mg/day, n = 441 |
---|---|---|---|
Age, mean (SD), years | 49.4 (10.1) | 49.9 (10.6) | 49.2 (11.0) |
Sex, n (%) | |||
Female | 213 (95.5) | 213 (95.1) | 423 (95.9) |
Male | 10 (4.5) | 11 (4.9) | 18 (4.1) |
Race, n (%) | |||
White | 211 (94.6) | 208 (92.9) | 412 (93.4) |
American-Indian/Alaska Native | 1 (0.4) | 2 (0.9) | 2 (0.5) |
Asian | 1 (0.4) | 1 (0.4) | 3 (0.7) |
Black | 7 (3.1) | 12 (5.4) | 17 (3.9) |
Other | 3 (1.3) | 1 (0.4) | 7 (1.6) |
Weight, mean (SD), lb | 181.9 (40.7) | 180.6 (41.4) | 181.3 (44.3) |
BMI, mean (SD) | 30.4 (6.5) | 30.4 (6.6) | 30.6 (7.4) |
FM duration, mean (SD), yrs | 6.0 (5.9) | 5.6 (5.3) | 5.5 (5.1) |
PED daily morning recall pain score (SD), range 0–100 | 68.3 (11.9) | 68.3 (11.5) | 69.4 (11.9) |
Paper VAS 24-h recall pain score (SD), range 0–100 | 74.3 (15.1) | 73.0 (16.0) | 73.9 (16.3) |
FIQ total score (SD), range 0–100 | 64.7 (13.4) | 65.1 (13.7) | 64.3 (14.4) |
SF-36 PCS score (SD) | 31.4 (7.8) | 30.8 (7.6) | 31.4 (8.0) |
SF-36 MCS score (SD) | 42.1 (12.1) | 42.4 (11.4) | 41.5 (11.7) |
BDI score (SD), range 0–63 | 14.1 (9.5) | 13.2 (7.7) | 14.4 (8.6) |
MFI total score (SD), range 20–100 | 67.0 (13.0) | 67.5 (13.1) | 67.8 (13.3) |
MASQ total score (SD), range 38–190 | 88.5 (19.2) | 88.4 (19.7) | 89.4 (18.1) |
BDI: Beck Depression Inventory; BMI: body mass index; FIQ: Fibromyalgia Impact Questionnaire; MCS: Mental Component Summary; MFI: Multidimensional Fatigue Inventory; MASQ: Multiple Ability Self-Report Questionnaire; PED: patient experience diary; PCS: Physical Component Summary; VAS: visual analog scale.